Home>>Signaling Pathways>> Others>> Guanylate Cyclase >>LY83583

LY83583

Catalog No.GC13857

inhibitor of soluble guanylate cyclase and of cGMP production

Products are for research use only. Not for human use. We do not sell to patients.

LY83583 Chemical Structure

Cas No.: 91300-60-6

Size Price Stock Qty
1mg
$24.00
In stock
5mg
$91.00
In stock
10mg
$135.00
In stock
50mg
$445.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

LY83583 is an inhibitor of soluble guanylate cyclase and of cGMP production [1].

Soluble Guanylate cyclase (sGC) is a heterodimeric enzyme involved in converting guanosine triphosphate to cyclic guanosine monophosphate. Soluble Guanylate cyclase is a critical component of the NO/cGMP signaling pathway, which has been involved in a number of important physiological processes, including smooth muscle relaxation and neurotransmission [2].

In human platelets, LY 83583 significantly antagonized the inhibitory effect of sodium nitroprusside and EDRF. LY 83583 attenuated the increases in intracellular cyclic GMP by sodium nitroprusside and EDRF [1]. Low concentrations of LY 83583 (≤ 0.1 μM) inhibited endothelium-dependent relaxations of rabbit aortic strips induced by acetylcholine or by the calcium ionophore A23187. Higher concentrations (≥ 0.3 μM) produced partial inhibition of relaxation to sodium nitroprusside and glyceryl trinitrate. LY 83583 (10 μM) showed no effect on cyclic AMP-mediated relaxations induced by isoprenaline or forskolin [3]. In cultured endothelial cells, treatment with LY 83583 (1 μM) rapidly and reversibly inhibited EDRF release. In the rat gastric fundus, LY 83583 (10 μM) inhibited the relaxation induced by nitric oxide (NO) [4]. In activated human neutrophils, LY-83583 (100 μM) inhibited the release of both LF and MPO after stimulation with FMLP or A-23187. LY-83583 reduced the cGMP-dependent protein kinase (G-kinase) activity [5].

References:
[1] Mülsch A, Lückhoff A, Pohl U, et al.  LY 83583 (6-anilino-5, 8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation[J]. Naunyn-Schmiedeberg's archives of pharmacology, 1989, 340(1): 119-125.
[2] Denninger J W, Marletta M A.  Guanylate cyclase and the NO/cGMP signaling pathway[J]. Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1999, 1411(2): 334-350.
[3] Mülsch A, Busse R, Liebau S, et al.  LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase[J]. Journal of Pharmacology and Experimental Therapeutics, 1988, 247(1): 283-288.
[4] Barbier A J M, Lefebvre R A.  Effect of LY 83583 on relaxation induced by non-adrenergic non-cholinergic nerve stimulation and exogenous nitric oxide in the rat gastric fundus[J]. European journal of pharmacology, 1992, 219(2): 331-334.
[5] Wyatt T A, Lincoln T M, Pryzwansky K B.  Regulation of human neutrophil degranulation by LY-83583 and L-arginine: role of cGMP-dependent protein kinase[J]. American Journal of Physiology-Cell Physiology, 1993, 265(1): C201-C211.

Reviews

Review for LY83583

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for LY83583

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.